Inmune Bio, Inc.INMBEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Inmune Bio, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies to address unmet medical needs, including hard-to-treat hematologic malignancies, solid tumors, and neurodegenerative diseases such as Alzheimer's. Its lead product candidates modulate the innate immune system to improve patient outcomes across global key markets.
INMB Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.4M
Net Profit
$-6.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.24
Inmune Bio, Inc. Q3 FY2025 Financial Summary
Inmune Bio, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-6.5M (up 46.5% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-6.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Inmune Bio, Inc. Quarterly Revenue & Net Profit History
Inmune Bio, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-6.5M | N/A |
| Q2 FY2025 | $0 | — | $-24.5M | N/A |
| Q1 FY2025 | $50.0K | +257.1% | $-9.7M | -19478.0% |
| Q3 FY2024 | $0 | — | $-12.1M | N/A |
| Q2 FY2024 | $0 | — | $-9.7M | N/A |
| Q1 FY2024 | $14.0K | -63.2% | $-11.0M | -78750.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $14000 | $0 | $0 | $50000 | $0 | $0 |
| YoY Growth | -63.2% | N/A | N/A | 257.1% | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $46.8M | $52.5M | $52.8M | $37.8M | $37.7M | $33.4M |
| Liabilities | $17.8M | $15.4M | $14.1M | $8.1M | $8.8M | $8.0M |
| Equity | $28.2M | $36.3M | $38.7M | $29.7M | $28.9M | $25.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-7.5M | $-7.9M | $-7.0M | $-6.8M | $-7.4M | $-5.4M |